Contract development and manufacturing (CDMO) of biopharmaceuticals, including drug substances and finished products. Now — the numbers.
This is an established company with proven profits.
No real growth (5% a year).
The gap is $4.7B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 39.5× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
It pays out $3.19 per share each year — regular cash for whoever holds the stock.
The company’s market value is 40 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.